Understanding Benign Prostatic Hyperplasia and Its Treatment Options
Author Information
Author(s): Mark Emberton, Erik Cornel, Pier Francesco Bassi, Richard Fourcade, Jesús Maria Fernandez Gómez, Ramiro Castro
Primary Institution: Institute of Urology and Nephrology, University College London
Hypothesis
What are the risk factors and treatment options for managing benign prostatic hyperplasia (BPH) as a progressive disease?
Conclusion
Benign prostatic hyperplasia is a progressive disease that can be effectively managed with medical therapy, particularly through the use of 5-alpha-reductase inhibitors and combination therapy.
Supporting Evidence
- BPH is a chronic disease that can lead to complications like acute urinary retention and surgery.
- 5-alpha-reductase inhibitors can reduce prostate volume and improve symptoms.
- Combination therapy with 5ARIs and alpha-blockers offers greater benefits than monotherapy.
Takeaway
Benign prostatic hyperplasia is a condition that can get worse over time, but there are medicines that can help make it better and reduce the chances of needing surgery.
Methodology
The article reviews existing literature on the epidemiology, risk factors, and treatment options for BPH, including clinical trials and longitudinal studies.
Potential Biases
Potential conflicts of interest due to author affiliations with pharmaceutical companies.
Limitations
The study relies on existing literature and may not account for all individual patient variations.
Participant Demographics
Men aged 40-79 years, with a focus on those with moderate-to-severe symptoms.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website